Abstract
For over half a century, the carbazole skeleton has been the key structural motif of many biologically active compounds including natural and synthetic products. Carbazoles have taken an important part in all the existing anti-cancer drugs because of their discovery from a large variety of organisms, including bacteria, fungi, plants, and animals. In this article, we specifically explored the literature from 2012 to 2018 on the anti-tumour activities reported to carbazole derivatives and we have critically collected the most significant data. The most described carbazole anti-tumour agents were classified according to their structure, starting from the tricyclic–carbazole motif to fused tetra-, penta-, hexa- and heptacyclic carbazoles. To date, three derivatives are available on the market and approved in cancer therapy.
Author supplied keywords
Cite
CITATION STYLE
Issa, S., Prandina, A., Bedel, N., Rongved, P., Yous, S., Le Borgne, M., & Bouaziz, Z. (2019, January 1). Carbazole scaffolds in cancer therapy: a review from 2012 to 2018. Journal of Enzyme Inhibition and Medicinal Chemistry. Taylor and Francis Ltd. https://doi.org/10.1080/14756366.2019.1640692
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.